journal article·2026-05-26

Dual-Scale Liposomal Assembly Enables Alveolar Macrophage-Targeted Gene Delivery in High-Altitude Pulmonary Edema and Acute Lung Injury

Jianling Zhao, Guangwei Shi, Haixiang Han, Mengjun Zeng, Lu Zhang, Jinjie Lai, Ying Chen, Huiquan Wang, Hairong Yu, Cong Zhang, Liqun Jiang

ACS Nano· Volume 20· Issue 20
Publisher page

Abstract

Inhaled nanocarriers must withstand aerosolization, reach disease-relevant lung cells, and release their cargo into the cytosol, requirements seldom met simultaneously. We introduce a dual-scale, pH-responsive liposomal platform (oLip-RA) that reversibly aggregates into >1 μm clusters at neutral pH to promote size-dependent recognition by alveolar macrophages (AMs), then stepwise disassembles in endo/lysosomes into nanoscale liposomes, enabling endosomal escape and delivery of therapeutics (e.g., RNAs, proteins, antibodies). By relying on size rather than ligands, oLip-RA achieves macrophage targeting without susceptibility to pulmonary surfactant coronas. Mechanistically, clustering distributes aerosol shear across intervesicle contacts, while high-curvature subliposomes resist membrane failure, conferring superior nebulization stability over giant vesicles. Nebulization studies showed that oLip-RA preserves structure and function across two nebulizer types and retains AM tropism. Single-cell lung cytometry confirmed preferential AM uptake in vivo . In a hypoxia-driven high-altitude pulmonary edema (HAPE) model, inhaled oLip-RA reprogrammed AMs from pro-inflammatory M1 to anti-inflammatory M2, thereby restoring endothelial function (increased nitric oxide signaling and decreased permeability), preserving epithelial fluid clearance, and reducing pulmonary edema. As a scope extension, in a streamlined test in a lipopolysaccharide-induced acute lung injury model likewise oLip-RA reduced edema and tracer leakage, supporting its broader applicability while keeping HAPE as the primary focus. Together, these results establish oLip-RA as a nebulization-ready platform that resolves the deposition-to-escape “size paradox” and enables macrophage-targeted gene therapy across hypoxic and endotoxin-induced lung injuries.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: High Altitude and Hypoxia · Immune cells in cancer · Cancer, Hypoxia, and Metabolism

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Xuzhou Medical University, Tongshan Road 209, Xuzhou 221009, China

Huaihai Hospital Affiliated to Xuzhou Medical University

Shanghai Frontier Health Pharmaceutical Technology Co., Ltd

Funding

China Postdoctoral Science Foundation

References (45)

Show source-provided references
1. 10.1186/s13020-021-00509-z10.1186/s13020-021-00509-z ↗
2. 10.1016/j.celrep.2016.09.00810.1016/j.celrep.2016.09.008 ↗
3. 10.1186/s11658-025-00750-610.1186/s11658-025-00750-6 ↗
4. 10.1093/emph/eoaa05210.1093/emph/eoaa052 ↗
5. 10.3390/ijms23201265610.3390/ijms232012656 ↗
6. 10.1093/ckj/sfad13510.1093/ckj/sfad135 ↗
7. 10.1152/ajplung.00208.202410.1152/ajplung.00208.2024 ↗
8. 10.1073/pnas.202313011810.1073/pnas.2023130118 ↗
9. 10.1016/j.talanta.2024.12656110.1016/j.talanta.2024.126561 ↗
10. 10.1136/thoraxjnl-2015-20803210.1136/thoraxjnl-2015-208032 ↗
11. 10.1016/j.imlet.2021.10.00810.1016/j.imlet.2021.10.008 ↗
12. 10.1152/ajplung.00326.200210.1152/ajplung.00326.2002 ↗
13. 10.1096/fj.202501079R10.1096/fj.202501079R ↗
14. 10.1097/CM9.000000000000200710.1097/CM9.0000000000002007 ↗
15. 10.1016/j.jconrel.2015.09.00410.1016/j.jconrel.2015.09.004 ↗
16. 10.1152/ajplung.1997.272.5.L98910.1152/ajplung.1997.272.5.L989 ↗
17. 10.1073/pnas.230496612010.1073/pnas.2304966120 ↗
18. 10.3390/ijms2115549710.3390/ijms21155497 ↗
19. 10.1016/j.jddst.2021.10273810.1016/j.jddst.2021.102738 ↗
20. 10.1016/j.jconrel.2022.05.00610.1016/j.jconrel.2022.05.006 ↗
21. 10.1016/j.biomaterials.2010.01.06510.1016/j.biomaterials.2010.01.065 ↗
22. 10.1039/C7CP02548C10.1039/C7CP02548C ↗
23. 10.1002/smsc.20240006610.1002/smsc.202400066 ↗
24. 10.1016/j.jcis.2024.08.24910.1016/j.jcis.2024.08.249 ↗
25. 10.1016/j.jconrel.2022.09.02110.1016/j.jconrel.2022.09.021 ↗
26. 10.1039/C7NR02350B10.1039/C7NR02350B ↗
27. 10.1016/j.ijpharm.2019.11898710.1016/j.ijpharm.2019.118987 ↗
28. 10.1016/j.colsurfb.2018.04.05410.1016/j.colsurfb.2018.04.054 ↗
29. 10.1021/acsami.6b0350510.1021/acsami.6b03505 ↗
30. 10.1186/s12890-023-02666-310.1186/s12890-023-02666-3 ↗
31. 10.1016/j.metabol.2020.15433810.1016/j.metabol.2020.154338 ↗
32. 10.1016/S0927-7765(02)00018-810.1016/S0927-7765(02)00018-8 ↗
33. 10.1038/s41467-021-22563-910.1038/s41467-021-22563-9 ↗
34. 10.1021/acs.jcim.3c0093610.1021/acs.jcim.3c00936 ↗
35. 10.1007/s11095-008-9562-y10.1007/s11095-008-9562-y ↗
36. 10.3389/fimmu.2020.60794510.3389/fimmu.2020.607945 ↗
37. 10.1016/j.jconrel.2025.01.03310.1016/j.jconrel.2025.01.033 ↗
38. 10.1039/D4BM00174E10.1039/D4BM00174E ↗
39. 10.1016/j.biomaterials.2024.12271210.1016/j.biomaterials.2024.122712 ↗
40. 10.1021/acs.nanolett.2c0347510.1021/acs.nanolett.2c03475 ↗
41. 10.1021/acsami.9b0577210.1021/acsami.9b05772 ↗
42. 10.1016/j.polymer.2022.12537510.1016/j.polymer.2022.125375 ↗
43. 10.1021/acs.molpharmaceut.3c0114610.1021/acs.molpharmaceut.3c01146 ↗
44. 10.1016/j.bbrep.2021.10091610.1016/j.bbrep.2021.100916 ↗
45. 10.3390/toxins1202006210.3390/toxins12020062 ↗